Comparison of Acute Kidney Injury During Treatment with Vancomycin in Combination with Piperacillin-Tazobactam or Cefepime

Study Objective To evaluate the observed incidence of acute kidney injury (AKI) in adult patients receiving either piperacillin‐tazobactam and vancomycin or cefepime‐vancomycin for more than 48 hours. Design Retrospective matched cohort. Setting Large academic medical center. Patients Adult patients...

Full description

Saved in:
Bibliographic Details
Published in:Pharmacotherapy 2014-07, Vol.34 (7), p.662-669
Main Authors: Gomes, Diane M., Smotherman, Carmen, Birch, Amy, Dupree, Lori, Della Vecchia, Bethany J., Kraemer, Dale F., Jankowski, Christopher A.
Format: Article
Language:English
Subjects:
acute kidney injury
Acute Kidney Injury - chemically induced
Acute Kidney Injury - diagnosis
Adult
Aged
Anti-Bacterial Agents - administration & dosage
Anti-Bacterial Agents - adverse effects
Biological and medical sciences
cefepime
Cephalosporins - administration & dosage
Cephalosporins - adverse effects
Cohort Studies
Drug Therapy, Combination
Female
Humans
Kidneys
Male
Medical sciences
Middle Aged
Nephrology. Urinary tract diseases
nephrotoxicity
Penicillanic Acid - administration & dosage
Penicillanic Acid - adverse effects
Penicillanic Acid - analogs & derivatives
Pharmacology. Drug treatments
Piperacillin - administration & dosage
Piperacillin - adverse effects
piperacillin-tazobactam
Retrospective Studies
Treatment Outcome
Urinary system involvement in other diseases. Miscellaneous
vancomycin
Vancomycin - administration & dosage
Vancomycin - adverse effects
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Study Objective To evaluate the observed incidence of acute kidney injury (AKI) in adult patients receiving either piperacillin‐tazobactam and vancomycin or cefepime‐vancomycin for more than 48 hours. Design Retrospective matched cohort. Setting Large academic medical center. Patients Adult patients without preexisting renal dysfunction admitted over an 8‐month time period who received either the combination of piperacillin‐tazobactam and vancomycin or cefepime‐vancomycin for more than 48 hours were evaluated for AKI, defined by the Acute Kidney Injury Network criteria. Measurements and Main Results A total of 224 patients receiving either antimicrobial combination were evaluated for AKI. The incidence of AKI was significantly higher in the piperacillin‐tazobactam and vancomycin group (34.8%) compared with the cefepime‐vancomycin group (12.5%) in the unmatched analysis (p
ISSN:0277-0008
1875-9114
DOI:10.1002/phar.1428